Chronic Lymphocytic Leukemia Market

Market Overview:

The 7 major chronic lymphocytic leukemia markets reached a value of US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.62% during 2024-2034.

The chronic lymphocytic leukemia market has been comprehensively analyzed in IMARC's new report titled "Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which the healthy white blood cells (lymphocytes) in the bone marrow start mutating or changing into cancerous cells. This occurs when an abnormally large number of lymphocytes proliferate, pushing out normal blood cells and making it harder for the body to fight infection. The disease is classified into B lymphocytes and T lymphocytes, depending on the type of cells affected. The common symptoms associated with this ailment include enlarged and painless lymph nodes, fatigue, fever, pain in the upper left portion of the abdomen, night sweats, unexplained weight loss, easy bruising, etc. Individuals suffering from CLL may also experience frequent infections, anemia, and enlargement of the spleen. Diagnosing this condition typically requires an evaluation of the patient’s medical history and clinical features. A complete blood count test that reveals a significant number of mature lymphocytes and smudge cells is often used to confirm the diagnosis. The healthcare provider may also perform several other examinations, including genomic testing, flow cytometry, imaging studies, bone marrow aspiration, biopsy, etc.

The increasing cases of genetic disorders that can cause multiple gene mutations in the DNA are primarily driving the chronic lymphocytic leukemia market. In addition to this, the expanding geriatric population, who are more vulnerable to CLL due to a greater frequency of comorbidities, reduced organ function, and functional impairment, is also bolstering the market growth. Furthermore, the widespread adoption of monoclonal antibodies in combination with chemotherapy for treating this ailment by binding specific proteins to tumor cells and activating a mechanism that destroys them is acting as another significant growth-inducing factor. Additionally, the escalating demand for allogeneic stem cell transplantation, which can improve chances of long-term remission and boost overall health, is also creating a positive outlook for the market. Apart from this, the emerging popularity of chimeric antigen receptor T-cell therapy among patients, since it uses the body’s immune cells to locate and destroy the tumor, is expected to drive the chronic lymphocytic leukemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic lymphocytic leukemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic lymphocytic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic lymphocytic leukemia market in any manner.

Recent Developments:

• In March 2024, Bristol Myers Squibb disclosed that the U.S. FDA had granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor T cell therapy, for the therapy of adult patients with refractoryor relapsed chronic lymphocytic leukemia who have received at least two prior lines of treatment, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.
• In December 2023, Eli Lilly and Company announced that the FDA had approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the management of adult patients with chronic lymphocytic leukemia who have received at least two previous lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
• In December 2023, BeiGene, Ltd. announced that the U.S. FDA had approved a label update for BRUKINSA (zanubrutinib) to include improved progression-free survival results from the Phase 3 ALPINE clinical trial, which compared BRUKINSA to IMBRUVICA (ibrutinib) in previously treated patients with refractory or relapsed chronic lymphocytic leukemia.

Key Highlights:

• As per the National Cancer Institute, chronic lymphocytic leukemia affects 7.8 per 100,000 white men and 4.1 per 100,000 white women.
• Epidemiological studies have indicated that the frequency of chronic lymphocytic leukemia increases exponentially with age, peaking in the elderly.
• Males are approximately twice as likely to develop chronic lymphocytic leukemia as females.
• In India, the incidence rate of chronic lymphocytic leukemia is 0.41 per 100,000 people, which is ten times lower than in the United States.
• The average lifetime chance of developing chronic lymphocytic leukemia is around 1 in 175 (0.57%).

Drugs:

Bendamustine HCl (Treanda), an intravenously given alkylating drug, was authorized by the FDA after a priority review for treating patients with chronic lymphocytic leukemia. It functions as an alkylating agent, forming intra- and inter-strand crosslinks between DNA bases.

Epcoritamab is an experimental IgG1-bispecific antibody developed with Genmab's patented DuoBody technology. Genmab's DuoBody-CD3 technology directs cytotoxic T cells toward tumors, triggering an immune response against malignant cells. Epcoritamab targets both CD3 on T cells and CD20 on B cells, resulting in T cell-mediated death of lymphoma B cells.

Mosunetuzumab is under clinical development by Genentech USA and is currently in Phase II for refractory chronic lymphocytic leukemia. Mosunetuzumab is a bi-specific monoclonal antibody that operates by allowing one arm to target the B cell antigen CD20 while recruiting T cells by attaching to the T-cell receptor CD3. It comes in concentrated solution and solution for intravenous and subcutaneous injection.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic lymphocytic leukemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic lymphocytic leukemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic lymphocytic leukemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic lymphocytic leukemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic lymphocytic leukemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic lymphocytic leukemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic lymphocytic leukemia by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic lymphocytic leukemia across the seven major markets?
• What is the size of the chronic lymphocytic leukemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic lymphocytic leukemia?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Lymphocytic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic lymphocytic leukemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic lymphocytic leukemia market?
• What are the key regulatory events related to the chronic lymphocytic leukemia market?
• What is the structure of clinical trial landscape by status related to the chronic lymphocytic leukemia market?
• What is the structure of clinical trial landscape by phase related to the chronic lymphocytic leukemia market?
• What is the structure of clinical trial landscape by route of administration related to the chronic lymphocytic leukemia market?